<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="325">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02265237</url>
  </required_header>
  <id_info>
    <org_study_id>M11-665</org_study_id>
    <secondary_id>2014-001496-31</secondary_id>
    <nct_id>NCT02265237</nct_id>
  </id_info>
  <brief_title>A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)</brief_title>
  <official_title>A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study in HCV genotype 4-infected subjects with compensated cirrhosis is
      to assess the safety and to compare the percentage of subjects achieving a 12-week sustained
      virologic response (SVR12), [HCV ribonucleic acid (RNA) &lt; lower limit of quantification
      (LLOQ) 12 weeks following treatment], to a clinically relevant threshold [based on SVR rates
      for HCV genotype 4-infected subjects treated with pegylated interferon (pegIFN)/RBV].

      The 12 and 16-week arms have been fully enrolled. As of 19 May 2015, they were closed and
      the two 24-week arms were opened for enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of subjects with sustained virologic response 12 (SVR12) weeks post treatment</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid is less than the lower limit of quantification</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with treatment-emergent adverse events</measure>
    <time_frame>Up to 30 days following end of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Percentage of subjects who develop treatment-emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with SVR12 in subjects receiving 12 weeks of treatment compared to subjects receiving 16 weeks of treatment.</measure>
    <time_frame>12 weeks after last actual dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid less than the lower limit of quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with on-treatment virologic failure</measure>
    <time_frame>Up to 24 weeks after first dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid greater than lower limit of quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with post-treatment relapse</measure>
    <time_frame>Within 12 weeks after the last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid greater than lower limit of quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with SVR12 in subjects receiving 16 weeks of treatment compared to subjects receiving 24 weeks of treatment.</measure>
    <time_frame>12 weeks after last actual dose of study drug.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid less than the lower limit of quantification</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>ombitasvir/ABT-450/ritonavir + Ribavirin (RBV) for 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/ritonavir + Ribavirin dosed for 12 weeks for genotype 4 treatment-naive and treatment-experienced with IFN/RBV only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ombitasvir/ABT-450/ritonavir + Ribavirin (RBV) for 16 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/ritonavir + Ribavirin dosed for 16 weeks for genotype 4 treatment-naive and treatment-experienced with IFN/RBV only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 4 treatment-naive and experienced with IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/ritonavir + Ribavirin dosed for 24 weeks for genotype 4 treatment-naive and treatment-experienced with IFN/RBV only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 4 SOF/pegIFN/RBV or SOF/RBV treatment failures</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/ritonavir + Ribavirin dosed for 24 weeks for genotype 4 SOF/pegIFN/RBV or SOF/RBV treatment failures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ombitasvir/ABT-450/ritonavir</intervention_name>
    <description>tablets</description>
    <arm_group_label>ombitasvir/ABT-450/ritonavir + Ribavirin (RBV) for 12 weeks</arm_group_label>
    <arm_group_label>ombitasvir/ABT-450/ritonavir + Ribavirin (RBV) for 16 weeks</arm_group_label>
    <arm_group_label>Genotype 4 treatment-naive and experienced with IFN/RBV</arm_group_label>
    <arm_group_label>Genotype 4 SOF/pegIFN/RBV or SOF/RBV treatment failures</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>tablets</description>
    <arm_group_label>ombitasvir/ABT-450/ritonavir + Ribavirin (RBV) for 12 weeks</arm_group_label>
    <arm_group_label>ombitasvir/ABT-450/ritonavir + Ribavirin (RBV) for 16 weeks</arm_group_label>
    <arm_group_label>Genotype 4 treatment-naive and experienced with IFN/RBV</arm_group_label>
    <arm_group_label>Genotype 4 SOF/pegIFN/RBV or SOF/RBV treatment failures</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Subjects must meet one of the following:

        Treatment-naive (Subject has never received antiviral treatment for hepatitis C infection)
        OR For Arms A, B, and C:

        - Treatment Experienced (Prior null responders, Partial responders or Relapsers to
        IFN/RBV)

        For Arm D:

          -  Treatment Experienced (Prior sofosbuvir (SOF) breakthrough/non-responder or Prior SOF
             relapser to SOF/pegIFN/RBV or SOF/RBV)

          -  Subject has plasma HCV RNA &gt; 1000 IU/mL at Screening

          -  Chronic HCV genotype 4 infection with cirrhosis

        Exclusion Criteria: - Positive test result at Screening for Hepatitis B surface antigen
        (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab).

          -  Current enrollment in another interventional clinical study, previous enrollment in
             this study, or previous use of any protease inhibitor, non-nucleoside polymerase
             inhibitor, or Nonstructural viral protein (NS) 5A inhibitor, either investigational
             or commercially available (including previous exposure to ABT-450 or ombitasvir), or
             receipt of any investigational product within 6 weeks prior to study drug
             administration. Prior use of any direct-acting antiviral will not be allowed, except
             for Arm D where prior experience with the nucleoside polymerase inhibitor, sofosbuvir
             with pegIFN/RBV or SOF with RBV is required.

          -  Any current or past clinical evidence of Child-Pugh B or C classification or clinical
             history of liver decompensation including ascites, variceal bleeding, or hepatic
             encephalopathy.

          -  Confirmed presence of hepatocellular carcinoma.

          -  Any cause of liver disease other than chronic HCV infection.

          -  Abnormal laboratory tests.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roula Qaqish, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130045</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130211</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135228</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129623</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129624</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129625</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129132</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129134</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129135</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129755</name>
      <address>
        <city>Toronto</city>
        <zip>M6H 3M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129756</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129759</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129522</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129523</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129518</name>
      <address>
        <city>Montpellier - Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129519</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129517</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129532</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129534</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129535</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129836</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129838</name>
      <address>
        <city>Athens</city>
        <zip>14564</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129837</name>
      <address>
        <city>Rhodes</city>
        <zip>85100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129530</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129525</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137354</name>
      <address>
        <city>Razzano (Milan)</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129529</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129619</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129618</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129621</name>
      <address>
        <city>Majadahonda, Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129675</name>
      <address>
        <city>Pontevedra</city>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129616</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 23, 2015</lastchanged_date>
  <firstreceived_date>October 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Compensated Cirrhosis</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Hepatitis C Genotype 4</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
